What is new in systemic lupus erythematosus
Reumatol Clin. 2015 Jan-Feb;11(1):27-32.
doi: 10.1016/j.reuma.2014.09.004.
Epub 2014 Nov 11.
[Article in
English,
Spanish]
Affiliation
- 1 Servicio de Reumatología, Hospital Doctor Negrín, Las Palmas de Gran Canaria, Las Palmas, España. Electronic address: iruafer@gobiernodecanarias.org.
Abstract
Systemic lupus erythematosus is a heterogeneous rheumatic systemic disease with extremely varied clinical manifestations and a diverse pathogenesis, as illustrated in this review on the most relevant new knowledge related to the disease. Topics such as anemia, pathogenesis, cardiovascular risk assessment, antiphospholipid syndrome, prediction of damage and recent advances in treatment, including tolerogenic and biological agents, are discussed. Relevant contributions regarding classical therapies such as corticosteroid and antimalarials and their optimal use, as well as the roll of vitamin D, are also referred.
Keywords:
Lupus eritematoso sistémico; Systemic lupus erythematosus.
Copyright © 2014 Elsevier España, S.L.U. All rights reserved.
MeSH terms
-
Anti-Inflammatory Agents / therapeutic use
-
Antiphospholipid Syndrome / etiology
-
Biological Factors / therapeutic use
-
Cardiovascular Diseases / etiology
-
Disease Progression
-
Humans
-
Lupus Erythematosus, Systemic* / drug therapy
-
Lupus Erythematosus, Systemic* / etiology
-
Lupus Erythematosus, Systemic* / immunology
-
Lupus Erythematosus, Systemic* / physiopathology
-
Risk Factors
-
Vitamin D / therapeutic use
-
Vitamins / therapeutic use
Substances
-
Anti-Inflammatory Agents
-
Biological Factors
-
Vitamins
-
Vitamin D